NEtwork to Control ATherothrombosis (NEAT Registry)

NCT04677725 | Unknown

• 1 other identifier: NEAT
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

NEAT is an observational cohort (Prospective registry of real world data) of patients with coronary and peripheral artery disease in an outopatient setting.

Conditions

Coronary Artery Disease; Peripheral Arterial Disease; Atherothrombosis

Outcome Measures

Primary Outcomes (6)

• Percentage of patients receiving evidence based therapies to reduce cardiovascular risk

  DOMAIN 1: Appropriate use of antithrombotic therapy

  Baseline

• Percentage of patients receiving evidence based therapies to reduce cardiovascular risk

  DOMAIN 2: Cholesterol control

  Baseline

• Percentage of patients receiving evidence based therapies to reduce cardiovascular risk

  DOMAIN 3: Blood pressure control

  Baseline

• Percentage of patients receiving evidence based therapies to reduce cardiovascular risk

  DOMAIN 4: Glycemic control / diabetes treatment

  Baseline

• Percentage of patients receiving evidence based therapies to reduce cardiovascular risk

  DOMAIN 5: Weight control

  Baseline

• Percentage of patients receiving evidence based therapies to reduce cardiovascular risk

  DOMAIN 6: Non-pharmacological intervention: In this domain, there are 2 items to be evaluated: 1) No smoking; 2) Physical exercise ≥ 150 minutes per week.

  Baseline

Secondary Outcomes (2)

• Percentage of patients receiving complete evidence based therapies to reduce cardiovascular risk

  6 and 12 months

• Percentage of patients with complete control of risk factors (blood pressure, cholesterol and glycemia)

  baseline, 06 and 12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with coronary and peripheral arterial disease in an outpatient setting

You may qualify if:

• Patients ≥45 years followed in ambulatory setting with ≥1 of the following 3 criteria:
• Documented coronary disease (≥1 criteria must apply):
• Stable angina
• History of Unstable Angina
• History of coronary angioplasty/stenting
• History of coronary artery bypass graft
• Myocardial infarction within the last 20 years
• Documented symptomatic Peripheral Arterial Disease (≥1 criteria must apply):
• Previous aorto-femoral bypass surgery, limb bypass surgery, or percutaneous transluminal angioplasty revascularization of the iliac, or infra-inguinal arteries, or
• Previous limb or foot amputation for arterial vascular disease, or
• History of intermittent claudication and one or more of the following: 1) An ankle/arm blood pressure (BP) ratio \< 0.90, or 2) Significant peripheral artery stenosis (≥50%) documented by angiography, or by duplex ultrasound.

You may not qualify if:

• Patients from institutions that don't provide the Institutional Authorization Term,
• Incapacity of follow-up in one year according to investigator judgment (severe neuropsychiatric condition, life expectancy \< 12 months)

Sponsors & Collaborators

• Hospital do Coracao: lead
• Bayer: collaborator

Study Sites (1)

Hospital Do Coração

São Paulo, São Paulo, 05410001, Brazil

Location

Related Publications (1)

• de Barros E Silva PGM, do Nascimento CT, Pedrosa RP, Nakazone MA, do Nascimento MU, de Araujo Melo L, Junior OLS, Zimmermann SL, de Melo RMV, Bergo RR, Precoma DB, Tramujas L, Lima EG, Dantas JMM, do Amaral Baruzzi AC, Flumignan RLG, de Oliveira Paiva MSM, Gowdak LHW, de Carvalho PN, de Figueiredo Neto JA, Silvestre OM, Fioranelli A, Vieira RD', Horak ACP, Miyada DHK, Kojima FCS, de Oliveira JS, de Oliveira Silva L, Pavanello R, Ramacciotti E, Lopes RD; NEAT Investigators. Primary results of the brazilian registry of atherothrombotic disease (NEAT). Sci Rep. 2024 Feb 20;14(1):4222. doi: 10.1038/s41598-024-54516-9.

  PMID: 38378735 DERIVED

MeSH Terms

Conditions

Coronary Artery Disease; Peripheral Arterial Disease; Thrombosis

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Atherosclerosis; Peripheral Vascular Diseases; Embolism and Thrombosis

Study Officials

• Pedro de Barros e Silva, MD, MHS, PhD

  Faculty

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 8, 2020
• First Posted: December 21, 2020
• Study Start: September 30, 2020
• Primary Completion: March 1, 2023
• Study Completion: April 1, 2023
• Last Updated: November 3, 2022

Record last verified: 2022-11

Locations

BR (1)